Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × orelabrutinib × 1 year × Clear all

Phase

Status

Recruiting 10 Active not recruiting 3 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Mantle-Cell 1 Lymphoma 1

Interventions

Drug Therapy 62 Cisplatin 62 Specimen Handling 61 Carboplatin 60 pembrolizumab 55 Oxaliplatin 54 Bevacizumab 51 Cyclophosphamide 50 Gemcitabine 49 Radiotherapy 47 Capecitabine 47 Magnetic Resonance Spectroscopy 45 Paclitaxel 44 Docetaxel 37 tislelizumab 35 Standard of Care 35 toripalimab 34 Biopsy 34 Injections 33 Fluorouracil 33 Immune Checkpoint Inhibitors 29 Surgical Procedures, Operative 28 fludarabine 27 Leucovorin 27 Irinotecan 24 venetoclax 23 Radiosurgery 23 Nivolumab 23 130-nm albumin-bound paclitaxel 23 lenvatinib 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡